Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin C/lead levels study

This article was originally published in The Tan Sheet

Executive Summary

Ascorbic acid (vitamin C) intake "may have public health implications for control of lead toxicity," Joel Simon, MD, University of California at San Francisco, and Esther Hudes, PhD, V-A Medical Affairs Medical Center, San Francisco, conclude in a study on the relationship of ascorbic acid to blood lead levels, published in the June 23/30 Journal of the American Medical Association. Simon and Hudes analyzed data collected from the Third National Health and Nutrition Examination Survey involving 19,587 participants between the ages of six and 90. "Our principal finding was that serum ascorbic acid level was inversely related to blood lead level among adults and youths enrolled in NHANES III," they state. However, no link between dietary intake and blood lead levels was observed, suggesting either dietary estimates were too imprecise to allow detection of the link or the elevated lead levels increase ascorbic acid turnover, thereby lowering levels of the nutrient, the study notes

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel